EASD 2019: The DEFINE-HF Study

Published: 04 Nov 2019

  • Views:

    Views Icon 220
  • Likes:

    Heart Icon 2
Average (ratings)
No ratings
Your rating

Dr Mikhail N Kosiborod (Saint Luke's America Heart Institute, Kansas City, US) discusses the DEFINE-HF study - Dapagliflozin effects on biomarkers, symptoms and functional status in HFrEF patients with or without diabetes.

Filmed on site at EASD 2019 by Radcliffe Cardiology.